CANF
Price
$0.34
Change
-$0.03 (-8.11%)
Updated
Dec 3 closing price
Capitalization
15.74M
Intraday BUY SELL Signals
ORMP
Price
$2.72
Change
-$0.03 (-1.09%)
Updated
Dec 3 closing price
Capitalization
108.26M
83 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

CANF vs ORMP

Header iconCANF vs ORMP Comparison
Open Charts CANF vs ORMPBanner chart's image
Can-Fite BioPharma
Price$0.34
Change-$0.03 (-8.11%)
Volume$824.73K
Capitalization15.74M
Oramed Pharmaceuticals
Price$2.72
Change-$0.03 (-1.09%)
Volume$90.51K
Capitalization108.26M
CANF vs ORMP Comparison Chart in %
CANF
Daily Signal:
Gain/Loss:
ORMP
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
CANF vs. ORMP commentary
Dec 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CANF is a StrongBuy and ORMP is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 04, 2025
Stock price -- (CANF: $0.36 vs. ORMP: $2.76)
Brand notoriety: CANF and ORMP are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CANF: 8% vs. ORMP: 50%
Market capitalization -- CANF: $15.74M vs. ORMP: $108.26M
CANF [@Biotechnology] is valued at $15.74M. ORMP’s [@Biotechnology] market capitalization is $108.26M. The market cap for tickers in the [@Biotechnology] industry ranges from $117.5B to $0. The average market capitalization across the [@Biotechnology] industry is $2.19B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CANF’s FA Score shows that 1 FA rating(s) are green whileORMP’s FA Score has 0 green FA rating(s).

  • CANF’s FA Score: 1 green, 4 red.
  • ORMP’s FA Score: 0 green, 5 red.
According to our system of comparison, ORMP is a better buy in the long-term than CANF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CANF’s TA Score shows that 4 TA indicator(s) are bullish while ORMP’s TA Score has 5 bullish TA indicator(s).

  • CANF’s TA Score: 4 bullish, 2 bearish.
  • ORMP’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, CANF is a better buy in the short-term than ORMP.

Price Growth

CANF (@Biotechnology) experienced а +7.41% price change this week, while ORMP (@Biotechnology) price change was -4.17% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.32%. For the same industry, the average monthly price growth was +1.23%, and the average quarterly price growth was +54.93%.

Reported Earning Dates

ORMP is expected to report earnings on Feb 25, 2026.

Industries' Descriptions

@Biotechnology (+0.32% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ORMP($108M) has a higher market cap than CANF($15.7M). ORMP YTD gains are higher at: 14.050 vs. CANF (-77.791). CANF has higher annual earnings (EBITDA): -8.91M vs. ORMP (-22.07M). ORMP has more cash in the bank: 97.9M vs. CANF (6.46M). CANF has less debt than ORMP: CANF (90K) vs ORMP (912K). ORMP has higher revenues than CANF: ORMP (2M) vs CANF (560K).
CANFORMPCANF / ORMP
Capitalization15.7M108M15%
EBITDA-8.91M-22.07M40%
Gain YTD-77.79114.050-554%
P/E RatioN/A2.72-
Revenue560K2M28%
Total Cash6.46M97.9M7%
Total Debt90K912K10%
FUNDAMENTALS RATINGS
CANF vs ORMP: Fundamental Ratings
CANF
ORMP
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
16
Undervalued
38
Fair valued
PROFIT vs RISK RATING
1..100
10098
SMR RATING
1..100
10094
PRICE GROWTH RATING
1..100
9440
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a65

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CANF's Valuation (16) in the Biotechnology industry is in the same range as ORMP (38) in the Pharmaceuticals Other industry. This means that CANF’s stock grew similarly to ORMP’s over the last 12 months.

ORMP's Profit vs Risk Rating (98) in the Pharmaceuticals Other industry is in the same range as CANF (100) in the Biotechnology industry. This means that ORMP’s stock grew similarly to CANF’s over the last 12 months.

ORMP's SMR Rating (94) in the Pharmaceuticals Other industry is in the same range as CANF (100) in the Biotechnology industry. This means that ORMP’s stock grew similarly to CANF’s over the last 12 months.

ORMP's Price Growth Rating (40) in the Pharmaceuticals Other industry is somewhat better than the same rating for CANF (94) in the Biotechnology industry. This means that ORMP’s stock grew somewhat faster than CANF’s over the last 12 months.

ORMP's P/E Growth Rating (100) in the Pharmaceuticals Other industry is in the same range as CANF (100) in the Biotechnology industry. This means that ORMP’s stock grew similarly to CANF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CANFORMP
RSI
ODDS (%)
Bullish Trend 7 days ago
73%
Bearish Trend 7 days ago
80%
Stochastic
ODDS (%)
N/A
Bearish Trend 7 days ago
82%
Momentum
ODDS (%)
N/A
Bullish Trend 7 days ago
76%
MACD
ODDS (%)
Bullish Trend 7 days ago
63%
Bullish Trend 7 days ago
80%
TrendWeek
ODDS (%)
Bullish Trend 7 days ago
76%
Bullish Trend 7 days ago
79%
TrendMonth
ODDS (%)
Bearish Trend 7 days ago
85%
Bullish Trend 7 days ago
81%
Advances
ODDS (%)
Bullish Trend 10 days ago
76%
Bullish Trend 10 days ago
82%
Declines
ODDS (%)
Bearish Trend 14 days ago
87%
Bearish Trend 21 days ago
81%
BollingerBands
ODDS (%)
Bullish Trend 7 days ago
72%
Bearish Trend 7 days ago
83%
Aroon
ODDS (%)
Bearish Trend 7 days ago
87%
Bearish Trend 7 days ago
82%
View a ticker or compare two or three
Interact to see
Advertisement
CANF
Daily Signal:
Gain/Loss:
ORMP
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ARAT0.02N/A
N/A
Arax Holdings Corp.
CRWKF63.99N/A
N/A
Cranswick PLC
FRGGF0.50N/A
N/A
Forge Resources Corp.
UURAF4.78N/A
N/A
Ucore Rare Metals, Inc.
YAHOF2.71N/A
N/A
LY Corporation

CANF and

Correlation & Price change

A.I.dvisor indicates that over the last year, CANF has been loosely correlated with ALDX. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if CANF jumps, then ALDX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CANF
1D Price
Change %
CANF100%
-6.86%
ALDX - CANF
46%
Loosely correlated
-7.25%
NEVPF - CANF
30%
Poorly correlated
N/A
TPST - CANF
27%
Poorly correlated
-0.98%
OABI - CANF
27%
Poorly correlated
-1.15%
ORMP - CANF
26%
Poorly correlated
+0.36%
More

ORMP and

Correlation & Price change

A.I.dvisor indicates that over the last year, ORMP has been loosely correlated with BTAI. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if ORMP jumps, then BTAI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ORMP
1D Price
Change %
ORMP100%
+0.36%
BTAI - ORMP
44%
Loosely correlated
-9.22%
INO - ORMP
44%
Loosely correlated
-0.52%
MBIO - ORMP
44%
Loosely correlated
-7.69%
ZNTL - ORMP
43%
Loosely correlated
-1.82%
RVMD - ORMP
42%
Loosely correlated
-0.65%
More